Skip to main content
NewslettersWatchlist

Oncolytics Bio(ONC-T)
TSX

Today's Change
Real-Time Last Update
Day Low1.50
Day High1.60
Open:1.60
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
BayStreet.ca
Pancreatic Cancer Battle Intensifies with Biotech Sector's Advanced Treatments
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Newswire.ca
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
BayStreet.ca
Biotech Innovations Drive Hope in Global Fight Against Pancreatic Cancer
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
Newswire.ca
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
BayStreet.ca
Rising Cancer Rates Drive Biotech Advancements Despite Political Hurdles
Baystreet
Stocks in play: Oncolytics Biotech Inc.
Newswire.ca
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
Newswire.ca
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032
BayStreet.ca
Biotech's Developments in Race Against Rising Cancer Rates Revealed
Newswire.ca
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
BayStreet.ca
Biotech Firms Intensify Efforts as Breast Cancer Strikes Younger Patients at Alarming Rate
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Baystreet
Stocks in play: Oncolytics Biotech® Inc.

Profile

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.